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 The benefits of influenza vaccination in the 
elderly individuals are the subject of serious discussion. 
Existing estimates of the efficiency of vaccines come 
mainly from observational studies that may be biased 
because of difficulties in detecting and correcting 
confounding factors [1-5]. At the same time, the World 
Health Organization (WHO) considers an annual 
vaccination to be the most effective influenza prevention 
strategy, it is recommended for the elderly people in many 
developed countries [6]. 
 The US Centers for Disease Control and 
Prevention (CDC) for the 2016-2017 season recommend a 
vaccination as the best way to prevent influenza in their 
recommendations for people aged 65 and older. These 
recommendations are based on the fact that this age group 
is subjected to an increased risk of serious complications 
from influenza if compared with young and healthy, as 
immune protection of an individual with age becomes 
weaker. Although influenza seasons may vary in grades of 
severity, most people over the age of 65 and older are the 
most susceptible to flu. Recently, for example, from 71% 
to 85% of seasonal deaths from flu occurred in people of 
this age, in addition, they accounted for 54-70% of 
hospital-related influenza (CDC, National Center for 
Immunization and Respiratory Diseases, 2017). Influenza 
in general is a significant component in an annual 
morbidity, and the persons aged ≥65 years belong to the 
groups with a high risk of complications [7-8]. 
 Over the past decade, the influenza vaccine rates 
in the age group of 65+ have risen from about 15% in the 
1960s up to 65% in the 1980s, while the mortality from an 
influenza infection among elderly people in response to an 
enhanced vaccination continued to increase. It was difficult 
to accept the fact that the vaccine does not protect the 
elderly, and in 2005 the National Institutes of Health of the 
United States intended to prove "once and forever" that 
concomitant or confounding factors should not block the 
essential benefit of the vaccine. Having studied all the data, 
they realized that the results confirm the growth of flu 
death since the routine vaccination of elderly Americans 
has become widespread [9]. 
 Most estimates of the influenza vaccine 
effectiveness are based on trials using a variety of designs 
and results that have provided a wide range of seniors [10-
11]. In addition, since most of these trials are observational, 
they are prone to bias. Confounding factors, such as either 
concomitant diseases or functional status, can affect the 
results, despite the proposed different methods of their 
correction [2, 12]. 
 Evidence-based medicine can not boast of a large 
number of randomized clinical trials of the anti-influenza 
vaccine effectiveness in the elderly due to ethical issues 
[13]. Over the past 20 years, the only large randomized 
clinical trial was to investigate an inactivated anti-
influenza vaccine in adults aged ≥60 years, which was 
performed during one season and limited to healthy 
subjects. This trial demonstrated a 58% reduction in the 
risk of serologically verified uncomplicated influenza 
infection in the patients aged 60-69, but no conclusive 
findings were made for the individuals aged ≥70 years, 
because the capacity of this study was insufficient to 
investigate the vaccination efficiency in this age group 
[13]. Moreover, an evidence of efficacy in healthy subjects 
aged 60-69 can not be related to the elderly at the age of 
70, since elderly age and concomitant diseases are 
associated with an increased risk of complications and the 
immune system weakening [14-20]. With respect to the 
lack of an evidence, based on randomized clinical trials, we 
use the results of observational, usually retrospective 
cohort trials that may be biased [21-22]. 
 Many observational trials compared the risk of 
death from pneumonia and overall mortality during 
hospitalization among the vaccinated and unvaccinated 
elderly people during an influenza season. At the same time 
for vaccinated subjects the mortality risk from all the 
causes was reduced by 50% and the one from pneumonia 
and influenza-related hospitalization, respectively was 27-
33% decreased [23-38]. 
 Some authors interpreted these results as an 
evidence that the influenza vaccine significantly reduced 
the risk of death and hospitalization in the elderly [11, 39-
43]. 
 At the same time, a survey published in 2007 by 
Lone Simonsen et al. states that the estimates of a risk 
reduction for the vaccinated and unvaccinated elderly 
individuals represent the data, which are not confirmed in 
laboratory, considered as a gold standard. Due to this 
finding, ≥50% mortality from all the causes for vaccinated 
elderly people during the flu season is unlikely, taking into 
account that the flu is at most 10% of all the deaths during 
its season [44], and therefore the vaccine against influenza 
can prevent 10% of deaths as much as possible, even if the 
vaccine efficiency is 100% in the elderly. 
 None of the randomized trials evaluating the 
effectiveness of the trivalent vaccine have been addressed 
exclusively to the persons aged ≥65 years, and this is due 
to ethical issues. A single study for live attenuated 
influenza vaccine in adults of 60 years and older showed a 
significant overall efficiency (42%, 95% CI: 21-57), with 
efficiency lower in the subjects aged 60-69 (31%) and 
higher in the persons aged ≥70 years, i.e. 57% [45]. 
 Cecilia Trucchi et al. (2015) in their report 
analyze the results obtained in four meta-analyzes, 
including both randomized and observational trials on the 
effectiveness of influenza vaccination in the elderly [41, 
46-49]. 
 Combined observational trials, all the meta-
analyzes showed a significant reduction in mortality from 
all the causes, while the efficacy varied from 68% to 74%. 
The vaccination effect is expected to be higher when the 
genetic match between circulating and vaccine strains is 
improved [50]. And this is not always the case. For 
example, for the flu season 2014-2015, the vaccine's 
effectiveness was only 14% for people over 50 years [51]. 
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At the same time, Peter A. Gross et al. observed a 
significant improvement in vaccination even in those 
seasons where the strain mismatches were shown [41]. 
 Tom Jefferson et al. (2010) noted the 
effectiveness of vaccine prophylaxis against 
hospitalization for either influenza or pneumonia, as well 
as mortality from all the causes, more pronounced in the 
seasons with a good strain match. While in the same Anna 
S. Dean et al. (2010) published a clustered randomized trial 
that showed that the anti-influenza vaccine could be 
effective in preventing those events, despite an incomplete 
vaccination [52].  
 Lamberto Manzoli et al. (2009), summarizing the 
results of the meta-analysis, noted that anti-influenza 
vaccines are effective to prevent influenza, hospitalization 
and death among elderly people, while Michael T. 
Osterholm et al. (2012) [47] also in reliance of the meta-
analysis results, believe that "evidence for protection in 
adults aged 65 years or older is lacking". 
 In broad terms, Cecilia Trucchi et al. (2015) 
believe that most evidences suggest that anti-influenza 
vaccines provide an adequate protection against natural 
infection in the elderly, susceptible to a high risk of 
influenza and complications of the flu [53-55]. However, 
the assessment of benefits of vaccines still depends on 
significant methodological problems [56]. There is an 
evidence of bias in available experimental studies that 
assess the effectiveness of an influenza vaccine, as well as 
that the existing methods of correcting confounding factors 
are not able to adequately control them [57]. Some of the 
results that have been evaluated in a comprehensive review 
by Lamberto Manzoli et al. (2012) seem strange because of 
the incomprehensible mismatch between a significant 
impact on mortality from all the causes in the elderly, as 
opposed to a more moderate effect on cardiovascular 
events. Lamberto Manzoli et al. concluded that "although 
the discrepancies between the results of the meta-analysis 
of using the seasonal vaccines to the elderly were revealed, 
most of them showed statistically significant efficiency, the 
value of which, however, differed significantly" [58]. 
 A solution could be the performance of the state-
funded adequate randomized clinical trials for the elderly, 
but this would be a very costly and ethically challenging 
proposition, since the use of influenza vaccines is 
recommended throughout the world for several years [54, 
55] and the issues of cost-effectiveness need to be properly 
reviewed during a recession [58]. 
 The most significant (albeit not indisputable) 
achievement of recent years can be called entering the 
market of high-dose vaccine (containing 4 times more 
antigen than standard), which is specifically designed for 
people over 65 years. This is due to a stronger immune 
response after vaccination (higher antibody production). 
There are two high-dose vaccines: Fluad and Fluzone 
High-Dose. 
 The results of Fluzone High-Dose clinical trial 
involving more than 30,000 participants showed that the 
adults of 65 years and older who received a high-dose 
vaccine get sick with flu and flu-related illness by 24% less 
than those who received the standard influenza vaccine. A 
high dose vaccine has been approved to be used in the 
United States since 2009. The adjuvant flu vaccine Fluad 
is made using an adjuvant MF59, which is designed to 
create a stronger immune response to vaccination. .In the 
Canadian observational trial of 282 people aged 65 years 
and older, conducted during the 2011-2012 season, Fluad 
was 63% more effective than conventional non-adjuvant 
influenza vaccines. There were no randomized trials 
comparing Fluad with Fluzone High-Dose. For the first 
time, the Fluzone High-Dose vaccine was approved for the 
2016-2017 season (CDC, 2017) and contained only 180 μg 
of hemagglutinin: A (H1N1) - 60 μg, A (H3N2) - 60 μg, B 
- 60 μg formaldehyde ≤100 μg octophenol ethoxylate ≤250 
μg. 
 The Vaccine Adverse Event Reporting System 
(VAERS) caution you on the general effects of Fluzone 
High-Dose, which include high doses: pain at the injection 
site, muscle aches, malaise and headache (this is not a 
complete list). 
 Two clinical trials evaluated the safety of Fluzone 
High-Dose. Trial 1 (NCT00391053, at 
http://clinicaltrials.gov) was a multi-center, double-blind, 
pre-licensed, held in the United States. Post-administration 
and systemic adverse events were more commonly seen 
after Fluzone High-Dose vaccination if compared with 
Fluzone. 
 Within 6 months after vaccination, 156 (6.1%) in 
the recipients of Fluzone High-Dose 93 (7.4%) there were 
developed serious adverse events. Deaths were not 
recorded within 28 days of vaccination. There were 
reported 23 cases of death within 29-180 days of 
vaccination: 16 (0.6%) among Fluzone High-Dose and 7 
(0.6%) among Fluzone recipients. Most of these 
participants had a history of cardiovascular, liver, 
neoplastic, renal and/or respiratory diseases. There was no 
cause-and-effect relationship between fatalities and 
Fluzone High-Dose vaccination.  
 Trial 2 (NCT01427309, http://clinicaltrials.gov) 
was a multi-center, double-blind, post-licensed study 
performed in the United States and Canada during two 
seasons of influenza. In this study, adults of 65 years age 
and older were randomized to receive Fluzone High-Dose 
or Fluzone (Stocks 2011-2012 and 2012-2013). The study 
compared the efficacy and safety of Fluzone High-Dose 
with Fluzone. The safety analysis set composed 15,992 
recipients of Fluzone High-Dose and 15,991 recipients of 
Fluzone. 
 During the observation period (approximately 6-8 
months after vaccination), in 1,323 (8.3%) recipients of 
Fluzone High-Dose and 1,442 (9.0%) of Flucone ones 
there were developed serious adverse events. Most of these 
participants suffered from one or more chronic 
concomitant diseases. Totally 167 deaths were reported 
during 6-8 months after vaccination: 83 (0.5%) among the 
Fluzone High-Dose and 84 (0.5%) among the Fluzone 
receipients. Within 30 days following the vaccination, 6 
deaths were reported: 6 (0.04%) among Fluzone High-
Dose recipients and 0 (0%) among Fluzone recipients. 
There was no cause-and-effect relationship between 
fatalities and Fluzone High-Dose vaccination. 
 Post-marketing data collection on Fluzone High-
Dose is ongoing. Since these messages are not 
standardized, they pass spontaneously from an uncertain 
population, it is not always possible to reliably estimate 
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their frequency or establish a causal relationship to the 
vaccine influence [51]. 
 Fluad vaccine contains MF59 containing 
squalene. It causes an inflammatory reaction and acts 
mainly on the macrophages located at the injection site. 
MF59 increases the absorption of antigen by monocytes 
and promotes its migration to the lymph nodes, stimulating 
the production of antibodies and T-cell immune response 
[59]. 
 The benefit of this stimulation to many 
researchers seems controversial, since the squalene can 
cause the chronic inflammation reactions in the body, 
including autoimmune diseases [60]. 
 Is there an alternative to influenza vaccine in the 
elderly, which does not produce so many questions and 
concerns? 
 One of the most active advocates of an alternative 
vaccine prophylaxis in the world is Donald Miller Jr. is a 
cardiac surgeon and professor of surgery at Washington 
University in Seattle. He is a member of Doctors for 
Disaster Preparedness, Dr. John J. Cannell and his 
colleagues, Dr. Joseph Mercola. They actively propose the 
use of vitamin D to prevent influenza, the logical 
justification is as follows: the flu virus lives with a person 
all year round, and new strains are formed during the "dead 
season". In the southern and northern temperature zones 
the epidemic of influenza occurs in the cold season, from 
October to March and from April to September, 
respectively. Influenza epidemics also occur in the tropics 
during the rainy season. 
 The reasons why the flu epidemic occurs in 
winter, i.e., when it is cold, e.g. either the fact that people 
are inside the premises in a close contact with each other, 
or that the more dry air dries out the mucous membranes 
and does not allow the body to expel the virus, or that the 
virus remains longer on cold open surfaces, such as door 
handles, do not explain why epidemics occur in the tropics. 
 However, there is an explanation of why the 
epidemic of influenza occurs both in the warm and in cold 
climate. During the epidemic of influenza, wherever it is, 
the atmosphere blocks the ultraviolet radiation of the Sun. 
In temperature zones beyond 35 degrees of the north or 
south latitude, in winter the Sun is at a fairly low angle so 
that the ozone layer absorbs and blocks short (280-315 
nanometers) ultraviolet waves. In the rainy tropics, heavy 
rain clouds also block ultraviolet rays during the rainy 
season. 
 The skin contains a derivative of cholesterol, 7-
dehydrocholesterol. In the skin under the influence of 
ultraviolet radiation, one of the carbon rings of this 
substance molecule is detached to form vitamin D. 
 The interest in vitamin D extraskeletal effects has 
rapidly grown over the last thirty years due to the 
identification of Vitamin D receptors (VDRs) in different 
systems, organs, and cell types [61, 62]. The biologically 
active form of vitamin D 1.25 (OH) 2D3 is produced by 
two hydroxylation reactions, the latter being mainly in the 
kidneys via 1α-hydroxylase (1α-ONAT). Binding of 
vitamin D active form to its receptor leads to the VDR 
heterodimerization with retinoid X receptors. The obtained 
complex binds to sensory elements in DNA and regulates 
the expression of several gene products involved into 
absorption and metabolism of calcium and phosphorus, the 
function of skeletal muscle, metabolism of bone tissue, 
function of parathyroid glands and regulation of 
inflammation [62]. 
 The effects of 1.25 (OH) 2D3 on regulation of 
both inherent and adaptive immune systems are string and 
their evaluation has been just started. VDR was detected in 
activated CD4+ and CD8 + T cells, B cells, neutrophils, 
monocytes, macrophages, and dendritic cells [63]. Vitamin 
D binding to VDR in macrophages, neutrophils and 
monocytes results in the secretion of an antibacterial 
peptide, a catelcidine, which plays an important role in 
innate immune defense, due to its ability to lyze bacterial 
cells [64]. Serum levels of 25 (OH) D were associated with 
the expression and functionality of some TLR receptors 
(toll like receptors), especially those involved into viral 
responses [65]. The activation of congenital immune 
receptors, such as TLR2, enhances the expression of VDR, 
1α-OHase and catelcidine, indicating the potential role of 
vitamin D in congenital immune responses against 
bacterial pathogens [66]. Vitamin D has also been shown 
to suppress the expansion of T cells and modulates the 
expression of cytokines with Th2 bias [67]. Vitamin D 
prevents the differentiation and proliferation of B-
lymphocytes and secretion of immunoglobulins. Other 
immune effects that have been attributed to vitamin D 
include the maturation of dendritic cells, which lowers the 
regulation of expression of major histocompatibility 
complex class II, and enhances treatment and presentation 
of the antigen, resulting in the induction of more tolerant 
cytokines such as IL-10. This change in the priming 
environment affects the differentiation of Th cells into Th2. 
 Potential clinical manifestations of the VDR 
presence in immune cells compose a possible role in 
autoimmunity, infectious diseases and cancer. For 
example, the link between vitamin D deficiency and an 
increased incidence of autoimmune diseases, namely, 
systemic lupus erythematosus, rheumatoid arthritis, 
multiple sclerosis and inflammatory bowel disease in 
humans, as well as an increase in frequency of autoimmune 
disorders in animal models with vitamin D deficiency, 
have recently been published and discussed in the 
publication of Barbara Prietl et al., 2013. It has been shown 
that vitamin D inhibits the growth of Mycobacterium 
tuberculosis in human macrophages through the secretion 
of antibacterial peptides [68]. Recent studies have also 
shown that vitamin D has a beneficial effect on the survival 
of patients with non-small-cell lung cancer and can act as 
an agonist of VDR [69] and a therapeutic agent for mutant 
lung cancer [70]. 
 Changed physiological functions, which lead to 
an impairment of the immune response to infectious 
diseases and to increased susceptibility, is a distinctive 
feature of aging [71]. This unregulated immune status is 
called as an immune loss [72-74]. During aging, there is a 
rise in colonization of epithelium and mucous surfaces with 
bacteria and fungi, reactivation of latent and chronic 
infections and increased susceptibility to infectious 
diseases [73, 75]. In addition, with aging the 
immunogenicity and effectiveness of prophylactic 
vaccines against bacterial and viral targets decrease [76, 
77]. Laura A. Coleman et al., 2016 showed that the 
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expression and function of the congenital immune 
receptors on macrophages and dendritic cells decreased 
with aging [78]. As well it has been shown that the reduced 
function of antigen-presenting cells promotes an immune 
dysfunction during aging, which can be reversed either by 
joint stimulation during vaccination or during the 
development of adjuvant vaccines [79-82]. 
 Can injections (or pills) of vitamin D prevent flu 
better than vaccines? There is good reason to believe that 
it cans [83]. Adrian R. Martineau et al. analyzed twenty 
five randomized controlled trials (11,321 participants aged 
from 0 to 95 years). Adding vitamin D reduced the risk of 
acute respiratory infections among all the participants (0.88 
corrected odds ratio, 95% 0.81-0.96 confidence interval, P 
for heterogeneity <0.001). In the analysis of subgroups, it 
was shown that protective effects were observed in those 
who received daily or weekly vitamin D without additional 
bolus doses (corrected odds ratio of 0.81, 0.72-0.91), but 
not for those who received one or several bolus doses 
(corrected odds ratio of 0.97, 0.86-1.10, P for interaction = 
0.05). Among those receiving either daily or weekly 
vitamin D, the protective effects were more pronounced in 
the patients with an initial level of 25-hydroxy vitamin D 
<25 nmol/l (corrected odds ratio of 0.30, 0.17-0.53) than in 
those with an initial level of 25-hydroxy vitamin D 
≥25 nmol/l (corrected odds ratio of 0.75, 0.60-0.95, P for 
interaction = 0.006). Vitamin D did not affect a part of 
participants who experience at least one serious adverse 
event (corrected odds ratio of 0.98, 0.80-1.20, P = 0.83). 
The evidence supporting these analyzes has been assessed 
as being of high quality. It was finally concluded that the 
vitamin D supplement was safe and generally protected 
against acute respiratory infections. Patients with vitamin 
D deficiency and those who did not receive bolus doses 
received the most benefit [83]. 
 To summarize, all that is lacking is the words of 
Professor Donald Miller: "A large multi-center randomized 
trial conducted over multiple flu seasons comparing 
vitamin D to a flu shot can show conclusively which is 
better and safer. But given the financial stakes 
underpinning the flu shots, and unpatentable vitamin D, 
who will fund it?" [84]. 
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PROPHYLAXIS OF INFLUENZA IN THE 
ELDERY. IS THERE ANY ALTERNATIVE? 
Grishyna O.  I., Babinets O. M., Menkus O. V., 
Kalchenko G. R. 
 
 The benefits of influenza vaccination in the 
elderly individuals are the subject of serious discussion. 
Evidence-based medicine can not boast of a large number 
of randomized clinical trials of the anti-influenza vaccine 
effectiveness in the elderly due to ethical issues. Over the 
past 20 years, the only large randomized clinical trial was 
to investigate an inactivated anti-influenza vaccine in 
adults aged ≥60 years, which was performed during one 
season and limited to healthy subjects. This trial 
demonstrated a 58% reduction in the risk of serologically 
verified uncomplicated influenza infection in the patients 
aged 60-69, but no conclusive findings were made for the 
individuals aged ≥70 years, because the capacity of this 
study was insufficient to investigate the vaccination 
efficiency in this age group. Moreover, an evidence of 
efficacy in healthy subjects aged 60-69 can not be related 
to the elderly at the age of 70, since elderly age and 
concomitant diseases are associated with an increased risk 
of complications and the immune system weakening. 
With respect to the lack of an evidence, based on 
randomized clinical trials, we use the results of 
observational, usually retrospective cohort trials that may 
be biased. We analyzed the results of randomized 
multicenter vaccine trials including Fluzone High-Dose 
Vaccine, meta-analysis data, and concluded that evidence 
for protection in adults aged 65 years or older is lacking. 
As an alternative, the results of clinical trials and a meta-
analysis of the effectiveness of vitamin D3 for the 
prevention of influenza / influenza-like illnesses are 
considered. The extraskeletal effects of vitamin D are 
analyzed. The interest in vitamin D extraskeletal effects 
has rapidly grown over the last thirty years due to the 
identification of Vitamin D receptors (VDRs) in different 
systems, organs, and cell types. The effects of 1.25 (OH) 
2D3 on regulation of both inherent and adaptive immune 
systems are string and their evaluation has been just 
started. VDR was detected in activated CD4+ and CD8 + 
T cells, B cells, neutrophils, monocytes, macrophages, 
and dendritic cells. The results of the meta-analysis 
twenty five randomized controlled trials (11,321 
participants aged from 0 to 95 years) published by Adrian 
R. Martineau et al. were presented. The meta-analysis has 
found that adding vitamin D reduced the risk of acute 
respiratory infections among all the participants (0.88 
corrected odds ratio, 95% 0.81-0.96 confidence interval, P 
for heterogeneity <0.001). Vitamin D did not affect a part 
of participants who experience at least one serious 
adverse event (corrected odds ratio of 0.98, 0.80-1.20, 
P=0.83). It was finally concluded that the vitamin D 
supplement was safe and generally protected against acute 
respiratory infections.  A conclusion was drawn on the 
need for a large clinical trial comparing the efficacy and 
safety of a flu vaccine and vitamin D3. 
Key words: influenza, flu-related illness, flu vaccine, 
elderly, vitamin D3, extraskeletal effects.  
 
 
 
